In a nutshell, the larger data set announced on 11/6 is not as good as the smaller data set announce 3 days earlier and caused the crash. But, common! 53% overall response rate in melanoma is still incredible! ===================================================== On November 3, Incyte Corporation outlined its intention to advance studies of its wholly owned epacadostat and Merck's Keytruda into phase 3 trials for the first line treatment of advanced metastatic melanoma. Incyte also announced that it would present the first data from the combination therapy at the Society for Immunotherapy of Cancer conference, which it did today. As of November 3, safety data was available on 28 patients and efficacy data was available on 19 patients. Based on that information, the couplet appeared safe and demonstrated an encouraging trend toward "promising clinical efficacy", particularly in melanoma. Specifically, four of seven melanoma patients had an overall response to the therapy, or 57%, and disease control was seen in six of seven patients, or 86%. In today's presentation, insight was offered up on safety in 56 patients and efficacy in 47 patients, including 19 melanoma patients. Of those 19 melanoma patients, 10 had an overall response rate, or 53%, and disease control was seen in 14 patients, or 74%.
【在 m******c 的大作中提到】 : In a nutshell, the larger data set announced on 11/6 is not as good as the : smaller data set announce 3 days earlier and caused the crash. But, common! : 53% overall response rate in melanoma is still incredible! : ===================================================== : On November 3, Incyte Corporation outlined its intention to advance studies : of its wholly owned epacadostat and Merck's Keytruda into phase 3 trials for : the first line treatment of advanced metastatic melanoma. Incyte also : announced that it would present the first data from the combination therapy : at the Society for Immunotherapy of Cancer conference, which it did today. : As of November 3, safety data was available on 28 patients and efficacy data
【在 m******c 的大作中提到】 : In a nutshell, the larger data set announced on 11/6 is not as good as the : smaller data set announce 3 days earlier and caused the crash. But, common! : 53% overall response rate in melanoma is still incredible! : ===================================================== : On November 3, Incyte Corporation outlined its intention to advance studies : of its wholly owned epacadostat and Merck's Keytruda into phase 3 trials for : the first line treatment of advanced metastatic melanoma. Incyte also : announced that it would present the first data from the combination therapy : at the Society for Immunotherapy of Cancer conference, which it did today. : As of November 3, safety data was available on 28 patients and efficacy data